FENC - Earnings call 3 2023 | Fennec Pharmaceuticals Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Third Quarter 2023 Earnings and Corporate Update Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded.

Now I would like to turn the conference over to Fennec Chief Financial Officer, Robert Andrade. Please go ahead.

Robert Andrade

Thank you, operator, and good morning, everyone. provide us Call, Fennec review during results well joining XXXX Third our you update. as Conference business Earnings which as appreciate today Pharmaceuticals' for Quarter financial We general a we will

Joining me Rosty Chief Operating Officer; Executive Chief morning Adrian our Raykov, Haigh, our and Officer. Fennec from this is

today's discussed current these in in results the the subject risks begin, the making and actual forward-looking be I forward-looking and remind release and differ to Before statements. filings may will and event to like References uncertainties we that you to that are and results that are Securities made the company press to would during risks uncertainties this call, periodic Commission. from U.S. statements detail in disclosed with the company's Exchange in cause

date. In today as addition, as our of only this any relied on revise obligation upon any be subsequent statements. made specifically forward-looking our as representing forward-looking call views represent to update statements We and views disclaim or not any should of any

to now website, the is And This Fennec rebroadcast with on XX be where I the it for will that, will audio call being available over days. recorded call for conference Rosty www.fennecpharma.com, Raykov. next turn

Rostislav Raykov

the good in focus United on is to States the Thank review morning, call. will all this review everyone. Europe. and issued our we of to you, press PEDMARK of in and Robert, global U.K. updates underway efforts detail ongoing outlined financial prior third were earnings and The the today's including in opportunities, for call morning Further, approval recent this which commercial our quarter our the XXXX results, release launch

a more reported pleased $X.X that the tripling quarter million revenues represents our very of since this third XXXX. in million, strong PEDMARK than from QX. are XXXX $X.X delivered increase report quarter second over revenue QX of Further, to XX% We

even launch and of the we to sustain We momentum into we've remainder world head that is PEDMARK underway we with to with made are date, 'XX prouder continue to as of be and this progress the 'XX. very the throughout encouraged

Pet risk FDA 'XX. As pediatric X mark hearing older the first It therapy reduce of reminder, an a month approved September of by in and cisplatin-induced tumors. localized in only is to patients with loss non-metastatic age of was FDA-approved the the solid

PEDMARK We U.S. in launched in XXXX. October the

continues X-year So our anniversary pediatric and of fashion the commercially our since We're became and community supporting PEDMARK we're enthusiasm available. marked just grow. very team's PEDMARK on for ongoing to commercial for the proud college and progress

Annual had with the Pediatric International engage busy team fact, Association the Hematology/Oncology on Society Pharmacy Annual ototoxicity. saw robust We cisplatin-induced attended work. Society of season XXXX the where Pediatric fall our Meeting, in we heard leaders and simply Health Full discussions Oncology Meeting, the and Annual the of of Oncology Tissue a of Hospital In Connect key Connective the about Conference Partners firsthand issue Nurses opinion importance the Meeting, the

which proceeds sponsored Cancer Hillsdale in the went multiple cancer. Day This an from on is organizations the engaged where of conference the football fight heels support College against in event day to Pediatric Awareness the we childhood game followed

of strong community. just relationships within build are to are we few how a These continuing examples the

solid mark to child a as prescribing complementary a for commercial terms In with of efforts Bed tumor. a when therapy establish non-metastatic cisplatin-based a agent necessary localized

and hospital the and targeting including centers, institutions sales use. of XX% CI ACM that U.S. COG is force cisplatin XXX pediatric Our currently across drive

prescription. written have we a Based on XX% estimate these PEDMARK approximately efforts,

from double-digit by We're the and prescribing orders new third PEDMARK In some under the fact, centers centers of leading with the quarter's existing growth patients we consistent that care. highly accounts. of prescribed have already more XX% pediatric eligible believe repeat in than encouraged hospital their the

in including success third at see continued quarter. to major formulary the hospital centers, academic several centers Further, approvals we in pediatric large continue

Geographically, our HCPs adoption within highly PEDMARK, prescribe are have our encouraging have target time. seen we and increasing territories seen over all of accounts that

utilization and continues several to types, have party evidenced germ with across including tumor PEDMARK In and and coverage, hepatoblastoma, plans also by osteosarcoma approved tumors. terms U.S. of cell have payer insurance we favorable the commercial plans. prescription patients, claims seen as broad Medicare

both are and eligible The PEDMARK As product patients, to estimate a at remainder to to government-sponsored limited HEARS, to no program, is under insured them programs. PEDMARK financial have we source insured patient coverage cost with PEDMARK reminder, Fennec no connect among support. designed commercially through may and current be approximately XX% access another our assistance receive single program patient patients which or XX% insurance comprehensive

we in Union announced treatment which name regard first of significant need. of Europe, European be the marketed the will expanding unmet address area be in PEDMARQSI will to EMA PEDMARK, the only PEDMARQSI. approved the medical approval June With to in this and under

Products and for MHRA, in PEDMARQSI Healthcare Medicines the same U.K. approved in indication. the the Agency, Further Regulatory October,

hearing Institute up U.K. Following key research in London. center PEDMARQSI we organized relationships, biomedical date and this presented leader UCLH at our earlier summit on by fall, therapeutic a and with RNID opinion background strong on the UCL

opportunity either We it in with a significant Europe see pathway continue Whatever value. pathway to we to evaluate company for the we the create commercial Europe alone and rest best world partner. the go shareholder another of is the select, or

the questions to to executing with in rapid the metastatic of Fennec child agent want as premier to partner therapy when on focus pediatric cisplatin-based a following: tumor, establishing is choice In among PEDMARK prescribing solid the I community. of in our barriers a minimizing commercial product localized and [indiscernible] oncology for closing, necessary responses remains establishing complement the reiterate access strategy

the been and the management on days and opportunities on Adrian, turn first share August over job. to Adrian, in will of to since now the executive has you. Fennec year's will over who I call Operating of that, team his of Officer. the With Chief his XXXX this Board Fennec Adrian after XXX joined observations

Adrian Haigh

joining Chief Operating as time Thanks, Rosty. Fennec Officer. months Indeed, full first it's few been an since exciting

the As in I've expressed priorities. August, got X call on

first we the the of continue as PEDMARK in launch The business. direction evaluate in of the accelerating is Europe second, U.S.; and to preparing for adoption the PEDMARQSI strategic

the Rosty As progress. adoption of PEDMARK in to U.S. continues make mentioned, solid

work standard number included and growth a to that PEDMARK care committees quarter is in adoption and all and existing the of of from customers as ensuring key with protocols. pharmacy orders benefited centers, key continue third from growth hospitals. and academic in We during importantly, repeat treatment We

NCCN expertise was To the therapeutics selling this we oncology our with a which year. young several committee strengthened achieved this we who adults, many Additionally, rating, effort, earlier sales hires, team AYAs. rating, focus where centers during XA X in adolescence further, of now community pharmacy And have the PEDMARK's we a AYA significant and putting support category on at leading third new institutions. patients the by we're treated. approval into opportunity endorsement and offered in importantly, have several are And increased won quarter,

we administration we've only centers, a strengthened of in purchasing infusion oncology will contracts organizations, the GPO number leading the in hospitals, with group and but these of endorsement Additionally, our focus relationship on the support and groups. signed managing not PEDMARK, centers community pediatric in home. use with the

a and to to bag leading with billing importantly, will the with direct pharmacy insurance provider hospital delivery home the Medicaid. specialty white also to be We to partnering provide administration or

PEDMARQSI in of the launch in steady the making We're preparation Europe. to for first half XXXX. the of progress Turning

X and include these German October the approval accepted. application. of XXXX, us allows activities German are price the was and in to Health at XXXX. This was Spain. in approval Some quarter dossiers now Assessment of sell Technology done hospitals France, price submission will for [indiscernible] it in stage advanced U.K., The required This during Italy PEDMARQSI Germany, and in the of development be submitted and an

countries pricing said, interactions we and reimbursement. early with received several Additionally, and And approval recently Rusty regarding in we've the key had favorable MHRA U.K. as

for to I'll over turn to quarter. that, Robert financials over the the Robert? With go call the

Robert Andrade

you, Adrian. Thank

our contains comments some results the release read website. than those details. for our the section It of XX-Q my with XXXX. through quarter Our third all financial press key our details, we of can Rather further today and on viewed filing will on financial focus of Media & results, week of be this anticipate Investors details

versus third growth XXXX approximately the of a revenue of recorded in for The company in net of second net quarter million the $X.X product XX%. sales million $X.X quarter

As has mentioned tripled the since from momentum the X Rosty, XXXX, building to more forward revenue than of net in look by XXXX. QX months and first we

recent growing hospital continuing ranges. To period the formulary reiterate our remarks the the within approvals pleased from quarter within OpEx Rosty and controlled and during Adrian, acceptance the third of access we QX. care remained with during and has well anticipated providers Overall, in early health are with PEDMARK

decrease The to employee lower compares XXXX General is $X.X in lower expenses legal the to second the quarter attributable and which and of administrative remuneration of expenses. quarter XXXX. were for $X.X million largely and administrative noncash third million

when expanded its began include As include and stated the quarters, payroll it out-of-pocket expenses. shipping previous expenses Selling and and expenses logistics, and recording sales distribution to an insurance, marketing force. in and internal wages advertising, costs, commissions company selling marketing

expenses pre-commercial million second XXXX in as in and expenses selling marketing the U.S. activities $X.X marketing third $X.X the in recorded compared increased the and to the company Europe. The of in company in quarter XXXX quarter million of

research the R&D received We when approval overall consistent and negligible it as levels expenses be quarter, PEDMARK. G&A. FDA in when expect costs fourth are to to but reduced including company QX with these of continue OpEx development the

R&D traditional or with associated recorded now sales. expenses of G&A capitalized PEDMARK of are product to as inventory The into cost majority eventually and recorded

net GAAP per $X.X XXXX. of per per $X.XX in share GAAP $X.X a million $X.XX loss of quarter or million and loss share loss for second in compared the of $X.XX or third quarter the to $X.X second of Our quarter million or net XXXX share was XXXX

progress results, in GAAP made closer As we breakeven have evident a in EPS. on significant to the getting

cash million which debt $XX cash our securities, million with investment under our the existing convertible ended capital Petrichor includes approximately We finally, And equivalents $XX.X third in drawn facility. quarter and of position. cash,

$X.X Our the was for compared quarter approximately burn to the XXXX. $X.X second cash in million of million quarter third

focused flow to on XXXX. a and the reaching in as breakeven reporting QX revenues our in cash U.S. As we progress reminder, grow look forward remain

believe coupled through we revenue our capital give our operations PEDMARK at Finally, us the with assumptions to when capital fund will XX next sufficient months. least available

ready for with questions. operator, are that, And we

Operator

[Operator with question Knickerbocker Chase from Instructions] comes first Craig-Hallum. Our

Chase Knickerbocker

seems to Maybe breakeven it seems your nice flow year. like Congrats executing that QX we initial on me. the plan me launch, you're was this model, just to If the where it expectation in on to look the quarter at cash start here. for

growing need the in business the nearly within my anything strong Looking breakeven operating at to center QX? is about thinking model, from that some commentary model? operations revenue deceleration penetration, or OpEx elevated drastic on right positive in income penetration or flow not revenue go sequentially, me Is meaningfully the about on cash to you with would when it post about there in paired caution with positive XXX% model centers, again a that like that would I the seems be of think you think the should way that forward the either I those

Rostislav Raykov

Yes. Perhaps that. Chase, question. answer Robert good can

Robert Andrade

Yes.

stated, controlled well previously OpEx the and remained our ranges. has period within As during guided

if the our it roughly For cash look million $X.X was to in OpEx, at specifically, third quarter expenses. million you $X

to So way to our based those on QX results, breakeven. are on we getting

existing this to PEDMARK Of the -- that us coupled grow, feel which, towards. operations we're an with to quarters we sufficient positivity. capital working evaluated our mentioned, in and launch, breakeven assumptions, does revenue give fund me. we cash, what But course, flow excuse further, evaluating, exclude as That's our we cash to will are EU comfortable when

Chase Knickerbocker

Great. meaningful I guess, generating me within deal? terms about should partner as that in XX U.K. or perspective months paired XX of within money more from go framework of think just decision color to for and well. there. X levels, And Maybe what most the a help upfront? Is a that, on first it the licensing of Is volume is the Europe Is then, whether Germany? on think investors alone? we it Just launch? country geographies with the Europe inform it royalty the about to a just Maybe that the kind

Rostislav Raykov

Adrian will he'll able and I from working for because Europe last over Chase. send days. Thanks, Dublin, in intimately XXX the it share his Yes. he's to been experience to be

Adrian Haigh

Chase, Yes, thanks question. for the

with chew. Europe, to all, I we alone, bite can of think off more we choose go we don't than if first

to sorry, ourselves, in it we -- major So major I we Europe. partner do if going in ourselves would it the the we in markets do were Western think

I've with been the discussions us achieve. what relationships establish develop are smaller perhaps dossiers, have to assessment look we and to of then views Europe vendors And say for I be able very we their to technology health the that had Eastern markets. helping on with that distributors will encouraged we've the some price that in by

at is when in covered argument economic these you of most the the -- the by you when of cover think deafness systems look are costs strong that very health I countries.

with associated deafness, heavily is example. Depression for

feel the price strong an has for a we months, So in submitted for said, first that can acceptable Europe. been make X accepted. we Germany, and as In argument we price I the

will and enter for the price. when we then we companies into at So insurance do that launch, the negotiations with price launch final

injection hefty helps. out all Europe, have we're And so said continuing then obviously, evaluate we approval submitted we in some or for an get we big with about preprice And looking cash to on, access application as in earlier be where If next options. royalties. to sales do But we early the early France that we'll license to application in an access if a year. submit should France, we're expect early

Chase Knickerbocker

versus bit a dig prior of we decline of bit of from the of the the thinking pricing kind of between And sales net if United in kind maybe maybe percentage greater on should little way have I States, in that also little the it about U.S. been bit XX% the how differently? Yes. then Is right think on usage of on sites side there. a be about then than perspective? outpatient And both color and or little a a outpatient a price coverage then from authorizations service kind inpatient Europe to

Adrian Haigh

see be is with than a -- more of XX% Yes, Germany and where Germany will initial the XXX% to then to we expect significantly pricing. What negotiation. request Okay. of sorry, to price closer some are for price in pricing based cap. subject the [indiscernible] we in U.S. kind Europe on I of

the where it will cost price what we a net of be of in the close high testicular EUR said to where negotiating the the million. came was cancer with patient -- XX-year-old out So discussions X were Germany they

of So be have we they won't health kind will covering we'll And think expect to EUR I cap. expect that. million, can that so some European X most authorities have

look around we're terms think if But pricing, I at looking U.S. you at of price in average. XX% the of an something

patients focus X,XXX With the U.S., population, focus who to we localized pediatric population, at look of the you are the treated have patient AYA the -- about turning disease numbers, a if the talk just cisplatin. in that's that with

one in add at in to about look cisplatin, cancer, AYA be are are you the U.S. patients patient to XX,XXX If the the just that testicular there cancer you if you're taking the the with X,XXX numbers population, other tumor in XX- treated types all group XX-year talking patients. And likely age

number patients. of tenfold a the increase potential So in

are And the in of course, it's most treated community, of patients and ASP-plus. these

started encouraging. the reporting this this reaction I early significant focusing and positive our on as are results been unmet just from that community. we So is said, medical very sales need have have sales population force a team there's and The

Operator

Naureen Instructions] from Securities. with One Capital [Operator Our comes next Quibria question

Naureen Quibria

simple with progress metrics over what and looking you're Just just in it kind I'll help. terms repeat time sales numbers there. at of specifics your you're orders? just Is some the actual on out start gauge quarter. you seeing progress? I just But curiosity, very are Congrats tracking personally guess would of to of

Rostislav Raykov

what we're get and and breakeven. send looking general, as In our is well. #X maybe Naureen, the it obviously, start it Robert to over to Adrian can priority to I for, business

So that we're almost from there perspective.

would And don't Robert and of -- in know, -- going add if forward, both to the we the on the Adrian, business like have population AYA sales based setting looking very the in terms side, on In absolutely going obviously, force be to those you'd the I sales discussed we're pediatric really incentivized or anything perform forward. brand well else? populations. to specific

Adrian Haigh

have a number of we Yes, metrics.

We have formulary committees, one.

and orders We -- have repeat from centers. orders those repeat

-- are it's and We sold ultimately, vials revenue. and obviously,

Naureen Quibria

And... it. Got

Rostislav Raykov

not their an based me They're they're territory and let -- and sorry, performance on in individual the add just overall [indiscernible]. based

Naureen Quibria

did mention in added folks you've the in some sales And remarks prepared Okay. that you force. the

if is just for could many little clarify So individuals focus up these bit? you that or you help now? are how newer different there to And a a

Rostislav Raykov

Yes.

we So -- we've for sales consistent. kept the are

in we some community use sold have discussed the calls force we've this and that right and XX% territories -- in also NCCN the as pick really now to to XX talented up are push salespeople team, the in now use. to cisplatin natural guidelines use the for the in looking -- sales We we target to in the can that focus, field turnover earlier some for PEDMARK of were of really you center can -- on And expand the this our based AYA the individuals of for imagine, is there yes, able population. we're some

think very we So well. out worked the just timing

Adrian Haigh

add if could there. And I

need there key are X, I actually. have think things or to X you

First the of all, category the with NCCN guidelines XA.

agreements Secondly, the from you place, organizations. in GPO have an need to endorsement the

need pharmacy specialty You home. the to patient's direct the that a to can supply direct to hospitals, community, the direct fund

then need used all to we in that And have this selling that now experienced of an place. and you sales is force environment in

focus a pediatric population away So the now major chipping oncology the at addition is AYA to centers. in

Naureen Quibria

Terrific.

one me. more just So from

partnering of that mention spec percentage that in angle, prepared You of curiosity. home and What market? with administration did, part angle. is remarks the of the admin pharma Just out Adrian, about your

Adrian Haigh

XX,XXX around think at for in But either those Well, centers in or are centers. you of said, if in hospitals. as specialist community oncology are pediatric older right centers, majority X,XXX oncology infusion treated ones And at patients, now, the or look treated total which there's there. the I home younger all then the accounts the probably the patients I

it's opportunity, And attractive. also where more we've NCCN are got financially bear in XA, heavier, and with going the we've it's they're because population mind the -- real patients older I lies opportunity in use got endorsement, that these vials. reimbursement AYA a So so obviously to and think the

Naureen Quibria

Right. Right.

Okay.

Rostislav Raykov

X this this add not to did this vials setting we of having for capability a more. patient, point, -- we provide have us ability The to to just we're And and up home capability, the now. into

So that's the earlier. certainly into mentioned in community encouraging skill very oncology, to required Adrian the set as addition to sell

suite on we sales to the plan. this and force the of have execute full So products

Adrian Haigh

of been has that October, the And middle of all place things. in since these

So we've there.. place got we think in everything

Operator

Duncan with comes Instructions] Charles [Operator Our question next Cantor Fitzgerald. from

Charles Duncan

quarter. a I Congrats good of on just them. couple had a

they're all, majority would of from forward younger use if the -- perhaps that folks, months pediatric from vial centers the next like And would just, your fast of more come the AYA it, revenue now, would beyond that you in of call it a you in it, population, for the cetera? you treated excellence et the or anticipate what over is call patients, year given First excellence course to generally be to from patient centers larger goal so achieve? for XX

Rostislav Raykov

Yes. Very good question.

we additional work the addition second mean, think to really AYA One been is that in all goal large and is center. a opportunities. is I -- the one focusing have I has Adrian we hospital on it's since done the international. the really X been with here, pediatric have

could all X of a these all X year I think that imagine we substantial from now, I contributing in speak amounts. them of would So place to things

size therapies nature PEDMARK. there, AYA, as by in more course, tumor the require would of the course, would of of significantly require there of very the we of patients, types more and the of the mentioned, treated cisplatin treated nature you And the vials larger significantly well the --

right as of under substantial the be hospital So that don't at I wins underestimate, activity it's yes, ones the hospital, as probably, progress. that There's good say But both mean, starting would probably still belt we amount we're would P&T largest. our newer given well the almost and that's pediatric made pediatric -- now, X I expecting.

pleasantly could there as So yes, also be we well. surprised

U.K., to and On is drive Germany the the right, side, really going -- international and of is France. course, is particularly there the what revenues

encouraged very been has So what Germany. Adrian by do in able certainly to

Charles Duncan

hearing can to and pharmacoeconomic if next a Adrian's I answers of the as of of about my little I on States? United the downstream to U.S.? Yes. regarding value in kind Do next a think of ex And what and strategy, on in the about being recognition pricing your gauge could year beyond in artifact of PEDMARK if be a half of segue is of great next pricing, country. talk confused here U.K. versus I able timing, the And you loss? it to an question. goal certain some a really steps the perhaps good conclusion able you a bit there's to guess come are that's or that could Europe know wondering costs for be to I'm talk to cisplatin-induced was the you first

Rostislav Raykov

Yes. to and I Adrian. one, would answer over send the latter I'll it

on now so that goal else, year would keeping rest the will partner next several that answer on or factors. to sometimes yes, on the we X the selling someone So our either right? to to ourselves So -- on what they and middle have doing, be all in the depend and of European business plan between major

Importantly, what upfront. the cash is

and -- over Adrian, to health of of PEDMARK European the their economics in the you proposition for held to systems. value health dossiers care terms So maybe, of

Adrian Haigh

Yes.

in is although the you've Europe got remind X think I now. that thing actually authorities everyone to So regulatory first of

U.K.'s countries. MHRA You've the other the and got XX the EMA,

afford different for XX country of a drug. ways to can assessing the got pay You've whether

clearer? And paying we to convincing preparation. will U.S. like something if XXX% able well So price putting least X in in countries We're XX% to can in are justify that terms at the terms Europe, the i.e., dossier European most strongly that the health of present argument advanced to together, we for of economic paying drug? argument be that's justify the we the of of country a feel in this

Charles Duncan

actual discount price. sense. if a didn't know Yes. or That makes I was it the

helps. So that

Adrian Haigh

for a will discounts mixture to I because whilst of they cancer of XX-kilo a X-kilo price full think be pay willing to a willing price be cap for they some won't full hepatoblastoma patient. degree testicular there will and be pay patient,

be cap. there's kind got of to So some

Charles Duncan

depression an the and sense. makes mentioned not ones a that I how to patient there as losing time. downstream the you cost community is recognition think only but hearing of And example of -- cost over That accrues

Adrian Haigh

And Yes. approaches. countries have different different

For is patient jobs, contribute school, of be account social the fact they will because security able -- don't example, unlikely they become some death well-paid take a they burden that out get to on to into there a drop the system.

countries example, their and into take will health much earnings, account just well, costing and will for are of taking into care in Some assessment. not system, that say, Others the how they account costs. cetera. loss social et security

So each slightly it. countries of has a these different way looking at one of

difficult generalized So a that justify I Where arguments we we've sufficiently would it's very to generalize. countries, that of strong to good most got the is in price. feel

Charles Duncan

That's helpful.

forward greater the and seeing progress quarter. U.S. in ex well the progress as to year next U.S. Looking as

Operator

[Operator ] with comes Instructions] Patel Wainwright. question Depesh next H.C. Our [ from

Unknown Analyst

U.S.? of This greater Ram Pet on for in of a cetera? patients commercial or disclose [ number to mark new trajectory Selvaraju. written ] instance, going total have of for prescribers the X is number you regarding for repeat Dipesh and prescription, forward What prescriptions information example, therapy, number you expect written, the prescribers kind of of et So do of than on number

Rostislav Raykov

good a that's -- question. can you Yes,

the we the As as particularly penetration the as the giving you building on within started right? And and with a those have more well the within physicians places. we could see, in granularity places P&T, accounts where started repeat as orders from little up those business

be think granular as will business on more we Absolutely. up, I So as builds the we I that. think

tumor what don't being treated. that label know, Keep of types mind, course, where in a that many that we the tumor are given best is case, types many, it covers what we're guessing our

Unknown Analyst

describe and formulary access have of reimbursement the PEDMARK? I would several status more Okay. questions. you And for How current

Rostislav Raykov

So issues. in major not seen any we terms of have reimbursement,

So that certainly has been encouraging.

In financial hospitals thin. of net could are the the margins U.S. imagine, formulary Their tremendous pressure. in under operating process, are margins, terms you as very

positive very level at happening is biosimilars. hand savings a is tremendous creating pharmacy from to particularly and they other their the them, On which are margin

obviously, get P&T moving a Those forward us to a through considerations, easy So all sometimes as given more It's play. are into P&T the that considerations it's easy. convenience, than their we through DRG. given takes type get not come from not But it to of once. comes this committee

Unknown Analyst

All when Europe how helpful. right. you progressing there? are to do then discussions And the and product partnership launch That's very in expect

Rostislav Raykov

quarter year. moment. I So we from next -- launch year, It's to probably second in expect guess question, next yes, our the best June just the May, sometime at the previous

We still be approved are X switching type our to they through the Europe, manufacture PEDMARQSI, have will a variation it's the so X going U.S. manufacturing basically from the also where PEDMARK, we're of into manufacturer and current type variation. in

to So on we think given into on the I able all is you work be. health we we'll as Adrian a preparation soon that launch and doing as certainly then more give economics. working he's label would product of obviously and then think ship the be market, I have little that European But the the granularity what month

Unknown Analyst

pipeline drug then from have questions. advance And other a Do stage you your it. more just any candidates time? at plans into Got clinic to this the the couple of discovery

Rostislav Raykov

which much if know history and X, we the but X. don't was have of with we the started about know I company Well, you

on it's one So something else establish us I to into the think before very market important bringing this in. for looking

Unknown Analyst

Got it.

Okay. And the U.S. PEDMARK long-term then does last competitive gentlemen. like for question, What look landscape the in

Rostislav Raykov

a cisplatin. a I very good how pediatric remain use and tumors to it. see most Oncologists pieces will are general treatment we in mean to They've for mainstay optimized AYA I cisplatin tumors drug. believe critical general would in It's in sensitive They pediatric know it the And the be. it. think cancer. use

on and the later cisplatin top comes usually comes of comes that else anything So stages. at

anyone replace cisplatin. to I So looking see don't

and the have we that view the really that's marketplace. So we in what see

any So yes, cisplatin I time soon. expect don't substitutions

Operator

remarks. not I'm this back time. over further questions the to for call Rosty any to turn any closing And like at I'd showing

Rostislav Raykov

like we our you, day. progress you in forward look and and great a future joining updating would continued have to milestones all to calls. today, you on thank Thank us I Yes. quarterly for launch and corporate

Operator

presentation. this gentlemen, Ladies does and today's conclude

have may disconnect, wonderful You and now a day.

Fennec Pharmaceuticals (FENC) 6 Nov 232023 Q3 Earnings call transcript